4 citations
,
June 2024 in “British Journal of Dermatology” EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.
16 citations
,
August 2014 in “Archives of Pharmacal Research” Special nanoparticles increased skin absorption of hair loss treatments with fewer side effects.
May 2010 in “OPAL (Open@LaTrobe) (La Trobe University)” Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
Blocking CXCR4 may help treat hidradenitis suppurativa.
2 citations
,
November 2004 in “Blood” RXRa is crucial for Th2 immune cell development and may link nutrition to immune health.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
2 citations
,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
CRISPR gene editing reduces harmful molecules in cells from Emery–Dreifuss Muscular Dystrophy patients.
5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
28 citations
,
September 2021 in “EMBO reports” Osthole inhibits the TRPV3 channel by binding to specific sites, potentially aiding drug development for skin diseases and cancers.
October 2025 in “Journal of the Endocrine Society” Finasteride lowers cholesterol but doesn't reduce heart-related events.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
The models can help find better inhibitors for conditions like baldness and prostate disorders.
20 citations
,
January 2016 in “Intractable & Rare Diseases Research” Combination therapy, especially with finasteride, is effective for treating frontal fibrosing alopecia.
1 citations
,
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Higher levels of certain proteins may increase or decrease rosacea risk.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
42 citations
,
April 2021 in “Pharmaceuticals” Five FDA-approved drugs may help block COVID-19 virus entry.
8 citations
,
January 2012 in “General and Comparative Endocrinology” 5α-Reductase helps regulate hormone action in toad testes, especially during breeding season.
A protein called sFRP4 can partly inhibit hair growth.
Certain Chinese herbs may help treat kidney fibrosis by targeting TGF-β.
41 citations
,
March 2017 in “PLoS neglected tropical diseases” Isotretinoin shows promise as a treatment for Chagas disease by effectively inhibiting key transporters in the parasite.
May 2024 in “JAMA Dermatology” Oral contraceptive use may increase the risk of frontal fibrosing alopecia in women with a specific CYP1B1 gene variant.
Activating CB1 can reduce keratin levels, potentially helping manage psoriasis and aid wound healing.
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
13 citations
,
January 2015 in “Steroids” The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
October 2017 in “The Journal of Urology” 5α-Reductase inhibitors can negatively impact sexual function.
May 2010 in “Europe PMC (PubMed Central)” Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.